Geno Germano, President and CEO, will provide an update on our next generation drug conjugate platform as well as our lead clinical program, ELU001, which targets folate receptor alpha. Geno and Ian Somaiya (CFO & CBO) are available for 1:1s during JPM week. #jpm2023 #jpm23
Elucida Oncology, Inc.
生物技术研究
Monmouth Junction，NJ 2,118 位关注者
A Clinical-Stage Biotechnology Company Targeting Cancer with Precision Engineered C'Dot Drug Conjugates
关于我们
Elucida Oncology, Inc., is a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small nanoparticle C’Dot drug conjugate (CDC) platform. CDCs are designed to penetrate deeper into tumors and deliver a significantly higher payload compared to antibody drug conjugates (ADCs). This combined with greater avidity for the target antigen, longer retention in tumors with minimal systemic exposure due to rapid renal clearance confers unique Target or Clear® properties. In preclinical studies, this has resulted in enhanced efficacy irrespective of antigen expression levels with reduced off-target toxicity, thereby potentially addressing the limitations of ADCs and other novel drug carriers.
- 网站
-
http://www.ElucidaOncology.com
Elucida Oncology, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Monmouth Junction，NJ
- 类型
- 私人持股
- 创立
- 2014